Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics

Journal of Clinical Pharmacology

Volumn 47, Issue 10, 2007, Pages 1320-1326

  Washington, Carla ^a   Hou, S Y Eddie ^a   Hughes, Nicola C ^b   Campanella, Corinne ^b   Berner, Bret ^a  

^a Pharmacokinetics Depomed Inc   (United States)

^b Biovail Contract Research   (Canada)

Author keywords

Drug interactions; Pharmacodynamics; Pharmacokinetics; Prolonged release ciprofloxacin; Warfarin

Indexed keywords

CIPROFLOXACIN; WARFARIN;

ADULT; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG HALF LIFE; ENANTIOMER; HUMAN; MALE; MONOTHERAPY; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SUSTAINED DRUG RELEASE; TABLET FORMULATION; VOLUNTEER;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-INFECTIVE AGENTS; ANTICOAGULANTS; CIPROFLOXACIN; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; STEREOISOMERISM; TABLETS; WARFARIN;

EID: 34648824852     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007305504     Document Type: Article

References (22)

1. Davis R., Markham A., Balfour JA Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 1996 ; 51: 1019-1074.
2. Vance-Bryan K., Guay Drp, Rotschafer JC Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet. 1990 ; 19: 434-461.
3. Foster RH, Keam SJ Prolonged-release ciprofloxacin. Am J Drug Deliv. 2006 ; 4: 113-120.
4. Washington C., Hou E., Hughes N., Berner B. Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin. Am J Health Syst Pharm. 2006 ; 63: 653-656.
5. ProQuin®XR. Prescribing Information. Menlo Park, Calif: Depomed, Inc ; 2005.
6. Fourcroy JL, Berner B., Chiang Y-K., Cramer M., Rowe L., Shore N. Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother. 2005 ; 49: 4137-4143.
7. Qaqish R., Polk RE Drug-drug interactions. In: Hooper DC, Rubinstein E, eds. Quinolone Antimicrobial Agents. 3 rd ed. Washington DC: ASM Press ; 2006: 133-146.
8. Wilkinson GR Drug metabolism and variability among patients in drug response. N Engl J Med. 2005 ; 352: 2211-2221.
9. Dugoni-Kramer BM Ciprofloxacin-warfarin interaction. DICP. 1991 ; 25: 1397.
10. Renzi R., Finkbeiner S. Ciprofloxacin interaction with sodium warfarin: a potentially dangerous side effect. Am J Emerg Med. 1991 ; 9: 551-552.
11. Kamada AK Possible interaction between ciprofloxacin and warfarin. DICP. 1990 ; 24: 27-28.
12. Linville D., Emory C., Graves L. Ciprofloxacin and warfarin interaction. Am J Med. 1991 ; 90: 765.
13. Mott FE, Murphy S., Hunt V. Ciprofloxacin and warfarin. Ann Intern Med. 1989 ; 111: 542-543.
14. Byrd DC, Gaskins SE, Parrish AM, Freeman LB Warfarin and ciprofloxacin interaction: case report and controversy. J Am Board Fam Pract. 1999 ; 12: 486-488.
15. Johnson KC, Joe RH, Self TH Drug interaction. J Fam Pract. 1991 ; 33: 338.
16. Ellis RJ, Mayo MS, Bodensteiner DM Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol. 2000 ; 63: 28-31.
17. Moore GC, Redfern J., Shiach CR, Webb K., Jones AM Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin. J Cyst Fibros. 2007 ; 6: 209-211.
18. Israel DS, Stotka J., Rock W., et al. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin Infect Dis. 1996 ; 22: 251-256.
19. Bianco TM, Bussey HI, Farnett LE, Linn WD, Roush MK, Wong YW: Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation. Pharmacotherapy. 1992 ; 12: 435-439.
20. Rindone JP, Kelley CL, Jones WN, Garewal HS Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin. Clin Pharm. 1991 ; 10: 136-138.
21. Coumadin® Prescribing Information. Princeton, NJ: Bristol-Myers Squibb ; 2006.
22. Kitaichi K., Nakayama H., Ueyama J., et al. Down-regulation of cytochrome P450 proteins and its activities by Shiga-like toxin II from Escherichia coli O157:H7. Biochem Pharmacol. 2004 ; 67: 1427-1435.